Contents
The goal of medical studies is simple: provide state-of-the-art and comprehensive care. Clinical research in Idaho offers the perfect opportunity for leading medical technology and pharmaceutical companies to revamp currently available treatments, drugs, and therapies.
Health volunteers are the backbone of medical discoveries. It is with your help that we make this possible.
Clinical Trials For Disease Areas in Idaho
Clinical research trials in Idaho are versatile. They target many diseases to find innovative solutions. Such as heart disease, neurological complications, bone and joint-related ailments, retinal conditions, and more.
The state of Idaho is also famous for its cancer research. Back in 2019, The Idaho State University Accelerator Center reported they could make a very pure type of medical isotope copper-67. This could be used in clinical trials to see how well it fights cancer.
Ready to make a difference? Browse our list below to find clinical trials you can apply for.
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho +12 locations
Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho
Saint Luke's Cancer Institute - Boise, Boise, Idaho
Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho
Kootenai Health - Coeur d'Alene, Coeur d'Alene, Idaho
Walter Knox Memorial Hospital, Emmett, Idaho
Saint Luke's Cancer Institute - Fruitland, Fruitland, Idaho
Idaho Urologic Institute-Meridian, Meridian, Idaho
Saint Luke's Cancer Institute - Meridian, Meridian, Idaho
Saint Alphonsus Medical Center-Nampa, Nampa, Idaho
Saint Luke's Cancer Institute - Nampa, Nampa, Idaho
Kootenai Clinic Cancer Services - Post Falls, Post Falls, Idaho
Kootenai Cancer Clinic, Sandpoint, Idaho
Saint Luke's Cancer Institute - Twin Falls, Twin Falls, Idaho
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
Recruiting
A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma.
A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma. Read Less
Gender:
ALL
Ages:
22 years and below
Trial Updated:
08/21/2024
Locations: St. Lukes, Boise, Idaho
St. Lukes, Boise, Idaho
Conditions: Neuroblastoma
Specimen Collection from Patients with Non-Hematologic Cancer for Use in Development of a Liquid Biopsy Assay
Recruiting
This specimen collection is designed to obtain whole blood and tumor tissue from subjects diagnosed with cancer for the purpose of the development of a noninvasive liquid biopsy assay using next generation sequencing (NGS).
This specimen collection is designed to obtain whole blood and tumor tissue from subjects diagnosed with cancer for the purpose of the development of a noninvasive liquid biopsy assay using next generation sequencing (NGS). Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/11/2024
Locations: Idaho Urology, Boise, Idaho
Idaho Urology, Boise, Idaho
Conditions: Non-hematologic Cancer
Neuroblastoma Maintenance Therapy Trial
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence. Read Less
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
09/18/2024
Locations: St. Lukes, Boise, Idaho
St. Lukes, Boise, Idaho
Conditions: Neuroblastoma
Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation
Recruiting
Prospective, controlled, multicenter clinical investigation with four trial cohorts: Randomized, Non-repairable, Severe Mitral Annular Calcification (MAC) and Severe Mitral Annular Calcification Continued Access Protocol (MAC CAP). Subjects in the Randomized cohort will be randomized in a 1:1 ratio to the trial device or to the MitraClip system. Subjects in the Non-repairable, Severe MAC, and Severe MAC CAP cohorts will receive the trial device.
The objective of the Clinical Trial to Evaluate t... Read More
Prospective, controlled, multicenter clinical investigation with four trial cohorts: Randomized, Non-repairable, Severe Mitral Annular Calcification (MAC) and Severe Mitral Annular Calcification Continued Access Protocol (MAC CAP). Subjects in the Randomized cohort will be randomized in a 1:1 ratio to the trial device or to the MitraClip system. Subjects in the Non-repairable, Severe MAC, and Severe MAC CAP cohorts will receive the trial device.
The objective of the Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation (SUMMIT) is to evaluate the safety and effectiveness of the Tendyne Transcatheter Mitral Valve System for the treatment of patients with symptomatic, moderate-to-severe or severe mitral regurgitation or for patients with symptomatic mitral valve disease due to severe mitral annular calcification.
This randomized controlled trial will provide the opportunity to evaluate the safety and clinical benefits of the Tendyne Transcatheter Mitral Valve System compared to the MitraClip System in patients with symptomatic, moderate-to-severe or severe mitral regurgitation, within approved MitraClip indications. In addition, the safety and effectiveness of the Tendyne Transcatheter Mitral Valve System will be evaluated in patients with severe mitral annular calcification who are at prohibitive risk for mitral valve surgery. Patients who are not suitable for mitral valve surgery for reasons other than severe mitral annular calcification and are also not suitable for transcatheter repair with MitraClip, will be enrolled in the Non-repairable cohort.
Subjects will be seen at screening, pre- and post-procedure, discharge, 30 days, 3 months, 6 months, and annually through 5 years. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: St. Alphonsus Regional Medical Center, Boise, Idaho
St. Alphonsus Regional Medical Center, Boise, Idaho
Conditions: Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases, Valve Disease, Heart, Heart Valve Diseases, Functional Mitral Regurgitation, Degenerative Mitral Valve Disease
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
Recruiting
This randomized phase II trial studies how well chemotherapy before surgery and radiation therapy works compared to surgery and radiation therapy alone in treating patients with nasal and paranasal sinus cancer that can be removed by surgery. Drugs used in chemotherapy, such as docetaxel, cisplatin, and carboplatin work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-... Read More
This randomized phase II trial studies how well chemotherapy before surgery and radiation therapy works compared to surgery and radiation therapy alone in treating patients with nasal and paranasal sinus cancer that can be removed by surgery. Drugs used in chemotherapy, such as docetaxel, cisplatin, and carboplatin work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy before surgery and radiation therapy may make the tumor smaller and reduce the amount of normal tissue that needs to be removed and treated with radiation. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho +5 locations
Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho
Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho
Kootenai Health - Coeur d'Alene, Coeur d'Alene, Idaho
Idaho Urologic Institute-Meridian, Meridian, Idaho
Saint Alphonsus Medical Center-Nampa, Nampa, Idaho
Kootenai Clinic Cancer Services - Post Falls, Post Falls, Idaho
Conditions: Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Recruiting
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading. Read Less
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/14/2024
Locations: Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho +2 locations
Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho
Saint Alphonsus Cancer Care Center-Nampa, Nampa, Idaho
Kootenai Clinic Cancer Services - Post Falls, Post Falls, Idaho
Conditions: Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Recruiting
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease.
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho +12 locations
Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho
Saint Luke's Cancer Institute - Boise, Boise, Idaho
Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho
Kootenai Health - Coeur d'Alene, Coeur d'Alene, Idaho
Walter Knox Memorial Hospital, Emmett, Idaho
Saint Luke's Cancer Institute - Fruitland, Fruitland, Idaho
Idaho Urologic Institute-Meridian, Meridian, Idaho
Saint Luke's Cancer Institute - Meridian, Meridian, Idaho
Saint Luke's Cancer Institute - Nampa, Nampa, Idaho
Saint Alphonsus Cancer Care Center-Nampa, Nampa, Idaho
Kootenai Clinic Cancer Services - Post Falls, Post Falls, Idaho
Kootenai Cancer Clinic, Sandpoint, Idaho
Saint Luke's Cancer Institute - Twin Falls, Twin Falls, Idaho
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Recruiting
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of... Read More
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho +12 locations
Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho
Saint Luke's Cancer Institute - Boise, Boise, Idaho
Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho
Kootenai Health - Coeur d'Alene, Coeur d'Alene, Idaho
Walter Knox Memorial Hospital, Emmett, Idaho
Saint Luke's Cancer Institute - Fruitland, Fruitland, Idaho
Idaho Urologic Institute-Meridian, Meridian, Idaho
Saint Luke's Cancer Institute - Meridian, Meridian, Idaho
Saint Alphonsus Cancer Care Center-Nampa, Nampa, Idaho
Saint Luke's Cancer Institute - Nampa, Nampa, Idaho
Kootenai Clinic Cancer Services - Post Falls, Post Falls, Idaho
Kootenai Clinic Cancer Services - Sandpoint, Sandpoint, Idaho
Saint Luke's Cancer Institute - Twin Falls, Twin Falls, Idaho
Conditions: Previously Treated Non-Small Cell Lung Cancer
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
Recruiting
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Ste... Read More
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Step 3) to either continue or discontinue the assigned treatment. Patients are treated for up to 7 years from Step 2 reg and followed for up to 15 years. Read Less
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/21/2024
Locations: Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho +12 locations
Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho
Saint Luke's Cancer Institute - Boise, Boise, Idaho
Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho
Kootenai Health - Coeur d'Alene, Coeur d'Alene, Idaho
Walter Knox Memorial Hospital, Emmett, Idaho
Saint Luke's Cancer Institute - Fruitland, Fruitland, Idaho
Idaho Urologic Institute-Meridian, Meridian, Idaho
Saint Luke's Cancer Institute - Meridian, Meridian, Idaho
Saint Luke's Cancer Institute - Nampa, Nampa, Idaho
Saint Alphonsus Cancer Care Center-Nampa, Nampa, Idaho
Kootenai Clinic Cancer Services - Post Falls, Post Falls, Idaho
Kootenai Clinic Cancer Services - Sandpoint, Sandpoint, Idaho
Saint Luke's Cancer Institute - Twin Falls, Twin Falls, Idaho
Conditions: Multiple Myeloma
Paid Clinical Trials in Idaho
Paid clinical trials open new doors for both researchers and health volunteers. By participating, you can get compensated for your work. This makes ID paid clinical trials a go-to choice for those looking to earn some cash or mitigate their medical expenses.
Phase 1 trials offer the biggest payment. They come with more risks (i.e. testing new medicine, unpredictable side effects, etc.), restrictions (i.e. don’t drink, follow a specific diet, don’t smoke, etc.), and are time-consuming. Phase 4 trials pay the least. Check the trial benefits before you apply.
Clinical Trials For Health Volunteers in Idaho
Your contribution not only advances cutting-edge treatments but also offers hope and a chance at a better future. Research teams in Idaho need health volunteers to propel their studies forward and make meaningful contributions to healthcare.
Find your path to medical discovery. Apply for trials today. Browse our list of clinical trials and be a part of the next breakthrough in medicine.
No trials could be found at this time
Medical Discoveries and Innovation in Idaho
Idaho research trials have left a mark on the field of healthcare. Here are some of the most impactful medical achievements that changed the lives of many patients.
- Telehealth Technology: Out of 44 Idaho counties, 35 are rural. Their access to healthcare is limited. So, the state made it a top priority to adopt telehealth technologies and revolutionize healthcare delivery. ID is now a leader in telemedicine.
- Environmental Factors Research: Experts from Idaho have collected substantial data that showcase the impact of climate change. The state’s changing climate conditions can help better understand how the summer and winter temperatures can affect agriculture, diseases, wildlife, and air quality.
- Studies of Infectious Diseases: Idaho’s Society of Epidemiologic Research is the oldest and biggest epidemiology society in North America. Experts from the community are actively involved in studying infectious diseases and treatments.
Why Idaho Is A Great Place For Clinical Research
Idaho clinical research can’t advance without the help of its people. Data shows that 81.1% of its residents are White, 13.3% are Hispanic, 2.2% are Multiracial, 1.5% are Asian, 1.1% are American Indian, 0.8% are Black.